Back to results
US 2026/0098294 A1Published application
Detection of minimal residual disease and cancer recurrence in drain fluid
AssigneeDroplet Biosciences, Inc.
InventorsWendy Winckler Adamovich, Seka Lazare
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the detection of minimum residual disease (MRD) in surgical drain fluid. The data collected from the drain fluid is also useful in predicting the recurrence of cancer. Comparison is also made between the analysis results of plasma and drain fluid.
Claims20
A method for predicting minimal residual disease, the method comprising the steps of obtaining a lymphatic exudate in proximity to a tumor;
- analyzing the lymphatic exudate to identify cfDNA that is detectable in the lymphatic exudate but that would be substantially undetectable in a blood sample obtained contemporaneous with the lymphatic exudate;
- and
- isolating the cfDNA;
- determining a sequence of the cfDNA;
- and
- predicting minimal residual disease based on results of the determining step.
3 more elements
A method for stratifying risk of recurrence in cancer patients, the method comprising the steps of:
- obtaining a lymphatic exudate sample from a patient;
- analyzing the sample to identify ctDNA that is detectable in the sample but not in a contemporaneously-obtained blood sample;
- determining a sequence of the ctDNA;
- and
- stratifying risk of cancer recurrence by analyzing the sequence of the cfDNA.
2 more elements
Dependencies are inferred from the claim text.